Mike Bereza – Page 3 – Online Prescribing

MDMA therapy for PTSD in Australia

By Mike Bereza January 12, 2024Empathogens, Psychedelic-Assisted Psychotherapy, PsychedelicsNo Comments

MDMA-assisted therapy has shown significant promise in the treatment of various psychiatric disorders, including post-traumatic stress disorder (PTSD), depression, and anxiety. This article provides an overview of the best practices…

Penetration Test Action Plan

By Mike Bereza January 11, 2024Cybersecurity, Digital Health, Distance Selling Pharmacy, NHS Pharmacy Commissioning, NHS Pharmacy LicenseNo Comments

This is to meet Evidence item 9.2.3 in the NHS DSP toolkit. i.e. The person responsible for IT has reviewed the results of the latest penetration testing, with an action…

List of MDMA Clinical Trials

By Mike Bereza January 11, 2024Empathogens, Psychedelic-Assisted Psychotherapy, PsychedelicsNo Comments

There has been a recent increase in interest in MDMA therapy as Lykos Therapeutics intends to launch MDMA as a licensed medicine towards the end of 2024. This marks a…

Understanding Health and Care Services

By Mike Bereza January 3, 2024NHS Pharmacy License, UncategorizedNo Comments

This document covers information needed by the NHS DSP Toolkit under Evidence item 7.1.1. Key attributes addressed include: i. What their key operational services are, ii. What technologies and services…

Pharmacy Training Needs Analysis (TNA) – Data Security and Protection

By Mike Bereza January 3, 2024Cybersecurity, Distance Selling Pharmacy, UncategorizedNo Comments

1. Introduction: Pharmacy Name: [Your Pharmacy Name] Date of Analysis: [Date] 2. Objectives: To assess the current knowledge and skills of pharmacy staff regarding data security and protection. To identify…

Pharmacy Privacy Notics for Data Security and Protection

By Mike Bereza January 3, 2024UncategorizedNo Comments

(Name and address of pharmacy) Privacy Notice We process your personal data, which includes your name, contact details, prescription medicines and data from other pharmacy and health care services we…

MDMA Therapy Sydney

By Mike Bereza January 1, 2024Depression, Neuropsychopharmacology, Psychedelic-Assisted Psychotherapy, PsychedelicsNo Comments

In 6 months (around June 2024) the FDA (US medicine regulator) will likely approve MDMA (ecstasy) as a licensed medicine in the US. This will present a pivotal moment for…

Pharmacy risk assessment for the sale of P medicines

By Mike Bereza October 16, 2023Online Prescribing, Paperless Pharmacy, Pharmacy Audit, UncategorizedNo Comments

If you are a distance-selling pharmacy attached to a private high street-based, pharmacy, the GPhC may want to inspect your premises to ensure that you are not offering face-to-face NHS…

Psilocybin Pills in the UK: An Overview of the Evolving Landscape

By Mike Bereza October 15, 2023Neuropsychopharmacology, PsychedelicsNo Comments

Note: As of October 2023, psilocybin remains a Class A drug in the UK. The following article provides informational content and does not endorse or encourage illegal activities. Always adhere…

Spravato Clinics Australia

By Mike Bereza October 15, 2023Depression, Psychedelic-Assisted Psychotherapy, Psychedelics2 Comments

As Australia continues to explore innovative treatments for treatment-resistant depression (TRD) and other mental health conditions, esketamine has emerged as a promising therapy. Delivered via nasal spray under the brand…